IR@PKUHSC  > 北京大学药学院  > 药剂学系
学科主题药学
Alzheimer′s disease progression model based on integrated biomarkers and clinical measures
Qiu, Yue1,2; Li, Liang1,2; Zhou, Tian-yan1,2; Lu, Wei1,2; Alzheimer′ s Dis Neuroimaging
关键词Alzheimer&prime s disease mild cognitive impairment A beta(42) p-tau hippocampus ADAS-cog disease progression model NONMEM
刊名ACTA PHARMACOLOGICA SINICA
2014-09-01
DOI10.1038/aps.2014.57
35期:9页:1111-1120
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Chemistry, Multidisciplinary ; Pharmacology & Pharmacy
研究领域[WOS]Chemistry ; Pharmacology & Pharmacy
关键词[WOS]COGNITIVE IMPAIRMENT ; IN-VIVO ; NEURODEGENERATION ; THERAPEUTICS ; AUTOPHAGY ; MELATONIN ; DEMENTIA ; ATROPHY ; PLAQUES ; TAU
英文摘要

Aim: Biomarkers and image markers of Alzheimer′s disease (AD), such as cerebrospinal fluid A beta(42) and p-tau, are effective predictors of cognitive decline or dementia. The aim of this study was to integrate these markers with a disease progression model and to identify their abnormal ranges.

Methods: The data of 395 participants, including 86 normal subjects, 108 early mild cognitive impairment (EMCI) subjects, 120 late mild cognitive impairment (LMCI) subjects, and 81 AD subjects were obtained from the Alzheimer′s Disease Neuroimaging Initiative (ADNI) database. For the participants, baseline and long-term data on cerebrospinal fluid A beta(42) and p-tau, hippocampal volume, and ADAS-cog were available. Various linear and nonlinear models were tested to determine the associations among the ratio of A beta(42) to p-tau (the Ratio), hippocampal volume and ADAS-cog.

Results: The most likely models for the Ratio, hippocampal volume, and ADAS-cog (logistic, E-max, and linear models, respectively) were used to construct the final model. Baseline disease state had an impact on all the 3 endpoints (the Ratio, hippocampal volume, and ADAS-cog), while APOE epsilon 4 genotype and age only influence the Ratio and hippocampal volume.

Conclusion: The Ratio can be used to identify the disease stage for an individual, and clinical measures integrated with the Ratio improve the accuracy of mild cognitive impairment (MCI) to AD conversion forecasting.

语种英语
WOS记录号WOS:000341225700002
项目编号U01 AG024904 ; P30 AG010129 ; K01 AG030514
资助机构Alzheimer&prime ; s disease Neuroimaging Initiative (ADNI, National Institutes of Health Grant) ; National Institute on Aging ; National Institute of Biomedical Imaging and Bioengineering ; Canadian Institutes of Health Research ; NIH ; Dana Foundation
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62372
专题北京大学药学院_药剂学系
作者单位1.Peking Univ, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
2.Peking Univ, Hlth Sci Ctr, Dept Pharmaceut, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Qiu, Yue,Li, Liang,Zhou, Tian-yan,et al. Alzheimer′s disease progression model based on integrated biomarkers and clinical measures[J]. ACTA PHARMACOLOGICA SINICA,2014,35(9):1111-1120.
APA Qiu, Yue,Li, Liang,Zhou, Tian-yan,Lu, Wei,Alzheimer&prime,&s Dis Neuroimaging.(2014).Alzheimer′s disease progression model based on integrated biomarkers and clinical measures.ACTA PHARMACOLOGICA SINICA,35(9),1111-1120.
MLA Qiu, Yue,et al."Alzheimer′s disease progression model based on integrated biomarkers and clinical measures".ACTA PHARMACOLOGICA SINICA 35.9(2014):1111-1120.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Qiu, Yue]的文章
[Li, Liang]的文章
[Zhou, Tian-yan]的文章
百度学术
百度学术中相似的文章
[Qiu, Yue]的文章
[Li, Liang]的文章
[Zhou, Tian-yan]的文章
必应学术
必应学术中相似的文章
[Qiu, Yue]的文章
[Li, Liang]的文章
[Zhou, Tian-yan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。